Study of a Rapid Triadic Communication Intention Elicitation Intervention to Improve Supportive Oncology Care Delivery (PRECursOr)
Pilot Study of a Rapid Triadic Communication Intention Elicitation Intervention (PRECursOr) to Improve Supportive Oncology Care Delivery for Patients with Advanced, Incurable Cancer and Their Caregivers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ashley Sheets
- Phone Number: 317-278-4315
- Email: ashnshee@iu.edu
Study Locations
-
-
Indiana
-
Carmel, Indiana, United States, 46032
- IU Health Joe and Shelly Schwarz Cancer Center
-
Indianapolis, Indiana, United States, 46202
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
patients will:
- be adult women with an incurable gynecologic cancer (i.e., evidence of refractory/progressive disease after first-line treatment or recurrent disease),
- not be receiving specialty palliative care or hospice,
- read/speak English, and
- be able to provide written informed consent.
caregivers will:
- identify as the individual who is primarily involved in the patient's care,
- be able to attend the oncology encounter,
- read/speak English, and
- be able to provide written informed consent.
providers will:
- specialize in gynecologic oncology, and
- provide outpatient care at IUSCCC gynecologic oncology clinic.
Exclusion Criteria:
patients and/or caregivers will be excluded if either one or both demonstrate:
- cognitive impairment, or
- speech/hearing difficulties precluding participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control group triads
|
|
|
Experimental: Intervention group triads
|
The intervention consists of a rapid (less than 10-minute) communication intention elicitation exercise (via Freelisting), which is conducted independently with the patient, caregiver, and provider immediately prior to the outpatient oncology encounter.
Patients, caregivers, and providers will not be instructed to endorse the Freelist responses that were generated by the intervention prior to the outpatient encounter-leaving the decision to discuss elicited communication intentions during the encounter up to individuals as the conversation naturally occurs.
As with the control group, post-encounter survey data will also be collected independently from the patient, caregiver, and the provider, followed by a post-encounter qualitative interview conducted jointly with the patient and caregiver.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate overall recruitment rates.
Time Frame: Once all surveys in the sample size are completed, 9 months anticipated
|
PRECursOr will meet or exceed feasibility (overall recruitment, recruitment rate, measure completion, encounter duration).
|
Once all surveys in the sample size are completed, 9 months anticipated
|
|
Evaluate overall participant satisfaction surveys.
Time Frame: Once all surveys in the sample size are completed, 9 months anticipated
|
PRECursOr will meet or exceed acceptability (satisfaction, acceptability of approach) benchmarks per patient and caregiver questionnaire.
|
Once all surveys in the sample size are completed, 9 months anticipated
|
|
Explore group differences in communication behaviors during the audio-recorded encounters.
Time Frame: Once all encounters in the sample size are completed and transcribed, 9 months anticipated
|
The intervention group will demonstrate increased communication behaviors during the encounter (i.e., breadth of supportive oncology domains discussed) and a trend toward greater benefits in the immediate (e.g., quality of communication) and proximal (e.g., shared understanding of treatment goals, distress, anxiety) outcomes of communication.
|
Once all encounters in the sample size are completed and transcribed, 9 months anticipated
|
|
Explore group differences in exit interview outcomes following the encounters.
Time Frame: Once all encounters in the sample size are completed and transcribed and survey/interview completion, 9 months anticipated
|
The intervention group will demonstrate increased communication behaviors and a trend toward greater benefits in the immediate (e.g., quality of communication) and proximal (e.g., shared understanding of treatment goals, distress, anxiety) outcomes of communication.
|
Once all encounters in the sample size are completed and transcribed and survey/interview completion, 9 months anticipated
|
|
Identify intervention approaches in exit interview that contributed to positive and/or negative outcomes
Time Frame: Once all surveys in the sample size are completed, 9 months anticipated
|
Identify intervention approaches that contributed to positive and/or negative outcomes to inform intervention refinement using qualitative research methods.
|
Once all surveys in the sample size are completed, 9 months anticipated
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Uterine Diseases
- Genital Diseases, Female
- Genital Neoplasms, Female
- Vulvar Diseases
- Vaginal Diseases
- Vulvar Neoplasms
- Uterine Neoplasms
- Vaginal Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- CTO-IUSCCC-0827
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.